Five-year survival with regional or distant spread is approximately 69% and 17%, respectively. Stage IIIC disease accounts for 8% of EC diagnoses, making it the most common locally advanced sub-stage (Surveillance, 2018, American Cancer Society. Cancer Facts and Figures, 2020, American Cancer ...
et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the prospective lynch syndrome database. Gut 67, 1306–1316 (2018). Article PubMed Google Scholar Ten Broeke, S. W. et al. Cancer risks for PMS2-associated lynch syndrome...
et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the prospective lynch syndrome database. Gut 67, 1306–1316 (2018). Article PubMed Google Scholar Ten Broeke, S. W. et al. Cancer risks for PMS2-associated lynch syndrome...
Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: evaluation of the pilot phase of the PORTEC-4a trial. Gynecol Oncol. 2018;151(1):69–75. https://doi.org/10.1016/j.ygyno.2018.07.020. Article CAS PubMed Google Scholar Leon-Castillo A, de Boer SM...
To evaluate the long-term health-related quality of life (HRQL) after external beam radiation therapy (EBRT) or vaginal brachytherapy (VBT) among PORTEC-2 trial patients, evaluate long-term bowel and bladder symptoms, and assess the impact of cancer on these endometrial cancer (EC) survivors. ...
“There’s emerging evidence that WEE1 inhibition might be effective in treating serous cancer,” Monk said. One agent targeting this pathway is adavosertib, which O’Malley said showed promising results in a small study that included 34 patients.18“[There was a] response rate of 29%, with...
The role of transvaginal sonography (TVS) in screening endometrial cancer and hyperplasia is significant in postmenopausal women. The objective of this study is to determine the endometrium thickness (ET) cut-off to distinguish premalignancy and malignan
Overall survival PFS: Progression-free survival TMB: Tumor mutation burden MAD: Median absolute deviation TOM: Topological overlap matrix KEGG: Kyoto encyclopedia of genes and genomes DEGs: Differentially expressed genes References Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estim...
Chemoresistance reduces the 5-year survival rate of endometrial cancer patient, which is the current major obstacle for cancer therapy. Increasing evidence state that Nrf2 contributes to chemoresistance in several kinds of cancer. However, its role in en
cancer death among women in the United States [3]. Approximately 10–15% of cases are diagnosed at an advanced stage, whereas those with advanced EC or recurrence have poorer survival outcomes, with an estimated five-year overall survival (OS) rate of 17% [2,4]. Known factors associated ...